by Richard Fried, MD, PhD; W. Phillip Werschler, MD; Judith Cenci, MD; Lauren Sternberg, MD; Priya Dhanaraj, MD; Dara Tolas, MA; and Suzanne Withrow, MA All authors except Dr. Werschler are with Yardley Dermatology Associates in Yardley, Pennsylvania. Dr. Werschler is Assistant Clinical Professor of Dermatology at the University of Washington School of Medicine in
Douglas Mest, MD; Gail Humble, MD, Blue Pacific Aesthetic Medical Group, Hermosa Beach, California Abstract Injectable poly-L-lactic acid is United States Food and Drug Administration–approved for the restoration and/or correction of the signs of lipoatrophy in people with human immunodeficiency virus and for use in immune-competent people for the correction of nasolabial fold contour deficiencies.
Richard N. Sherman, MD Skin Institute of New Orleans, New Orleans, Louisiana; Clinical Associate Professor, Department of Dermatology, Tulane University, New Orleans, Louisiana Disclosure: Dr. Sherman is a speaker, master trainer, and advisory board member for Sanofi-Aventis U.S. LLC. Editorial support for this article was provided by the editorial staff at Embryon. This article was
Michael H. Gold, MD Dr. Gold is the founder and medical director of Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser and Rejuvenation Center, and Tennessee Clinical Research Center located in Nashville, Tennessee. He is also Clinical Assistant Professor at Vanderbilt University School of Medicine and School of Nursing in Nashville, Tennessee;
Cherie M. Ditre, MD, Assistant Professor of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Editorial support for this article was provided by the editorial staff at Embryon. This article was funded by Dermik Laboratories, a business of sanofi-aventis U.S. The author gratefully acknowledges Patricia Bichler, PhD, who assisted in the preparation of this